Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...

This final season may be more of a cliffhanger than a conclusion. (A sequel is in the works.) The question it asks is: how ...

"We tried not to make the same show — it's got younger voices, it's got a completely different feel and a completely ...

As the sixth and final season lands on Hulu, THR’s chief TV critic reflects on how the dystopian series was shaped by the ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

The final season of "The Handmaid's Tale," premiering April 8 on Hulu, expands the themes and story of Margaret Atwood's ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

Hulu announced that it is developing a series based on Margaret Atwood's 2019 novel "The Testaments," which is a follow-up to ...

With the FDA appearing to be undergoing major disruption under new leadership, BofA analyst Tim Anderson says one way to assess the risk from ...

Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...